+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autologous Cell Therapies Market - Global Forecast to 2030- Product Image
Autologous Cell Therapies Market - Global Forecast to 2030- Product Image
Sale

Autologous Cell Therapies Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887813
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autologous Cell Therapies Market grew from USD 9.24 billion in 2024 to USD 10.62 billion in 2025. It is expected to continue growing at a CAGR of 14.63%, reaching USD 20.99 billion by 2030.

Autologous cell therapies are redefining the frontier of personalized medicine by harnessing a patient’s own cells to target disease with unprecedented precision. Rooted in the concept that individual-specific cells can be reprogrammed, expanded, and reinfused, these therapies minimize the risk of immune rejection while maximizing therapeutic efficacy. Over the past decade, breakthroughs in cell isolation techniques, expansion protocols, and delivery methods have accelerated clinical adoption across diverse therapeutic areas. This paradigm shift has been driven by a confluence of scientific advances in cell processing, regulatory adaptations that streamline investigational pathways, and strategic collaborations between academic centers and industry sponsors. As research teams deepen their understanding of cell behavior in vivo, the potential to address complex conditions-ranging from chronic degenerative disorders to aggressive malignancies-continues to expand. While early clinical successes have underscored the promise of autologous approaches in oncology and regenerative medicine, ongoing efforts to refine manufacturing scalability, reduce production costs, and strengthen supply chain resilience remain critical. By delivering high-value treatments that align with precision health initiatives, autologous cell therapies are poised to transform care delivery models and redefine long-term patient outcomes.

Transformative Shifts in the Landscape of Autologous Therapies

The landscape of autologous cell therapies is undergoing transformative shifts marked by technological innovation, regulatory evolution, and strategic partnerships. Gene editing platforms such as CRISPR/Cas9 and next-generation transcription activator-like effector nucleases (TALENs) have improved target specificity and enabled the creation of bespoke cellular products. Concurrently, automation and closed-system bioreactors are streamlining ex vivo expansion, reducing variability and accelerating time to treatment. Regulatory agencies are responding with adaptive frameworks that integrate real-world evidence and conditional authorizations for breakthrough therapies, thereby shortening review timelines without compromising safety standards. In parallel, the emergence of modular manufacturing hubs and distributed production models is mitigating geographic constraints and enhancing patient access. Strategic alliances between leading pharmaceutical companies, biotech innovators, and academic research institutes are facilitating the translation of academic discoveries into robust clinical pipelines. These synergistic collaborations often leverage shared data platforms and co-development agreements to de-risk early-stage programs and optimize resource allocation. Taken together, these shifts are propelling autologous cell therapies from niche investigational tools toward mainstream therapeutic options for complex diseases.

Cumulative Impact of United States Tariffs in 2025

The implementation of new United States tariffs in 2025 has introduced a significant recalibration of cost structures across the autologous cell therapy supply chain. Increases on imported single-use bioreactor components, proprietary culture media, and oxygenators have elevated input costs, prompting many developers to reassess supplier agreements and engage in strategic domestic sourcing. Providers are investing in local manufacturing partnerships to sidestep steep duties, while research centers are renegotiating reagent contracts to secure volume-based discounts. In addition, logistics and cold-chain operators are adjusting their pricing models to absorb cross-border fee hikes, potentially redirecting clinical trial shipments through cost-efficient transit corridors. Although the immediate impact has been a modest uptick in per-patient manufacturing expenses, mid-term strategies-such as backward integration of critical raw material supply and collaborative purchasing consortia-are emerging to mitigate tariff-induced pressures. This dynamic underscores the importance of supply-chain agility and proactive policy engagement for organizations seeking to maintain competitive pricing and uninterrupted clinical development.

Key Segmentation Insights for Autologous Cell Therapies

Deep segmentation analysis reveals nuanced insights that inform strategic priorities for autologous cell therapies. When dissected by technology type, the market encompasses two core pillars: cell therapy platforms, exemplified by hematopoietic stem cells and mesenchymal stem cells, and gene modification techniques, which include CRISPR/Cas9 and zinc finger nucleases. Assessment by application highlights cardiovascular diseases-spanning chronic heart failure and myocardial infarction-as well as oncology, where hematologic cancers such as leukemias and lymphomas intersect with solid tumors including breast cancer and lung cancer. In terms of end-users, the ecosystem integrates academic and research institutes, represented by clinical research organizations and university laboratories, commercial support entities like biotechnology and pharmaceutical companies, and hospitals differentiated between private and public institutions. Treatment type segmentation delineates allogeneic cell therapies versus autologous cell therapies, with the latter further categorized into combination therapy and monotherapy models. Insights by therapeutic area uncover two pivotal domains: autoimmune diseases, featuring multiple sclerosis subtypes of primary progressive and relapsing-remitting forms alongside rheumatoid arthritis, and regenerative medicine, which spans tissue engineering and wound healing applications. Finally, manufacturing process considerations oscillate between ex vivo expansion and in vivo stimulation, while source of cells analysis contrasts adipose tissue-derived cells with bone marrow-derived cells. This comprehensive segmentation framework enables stakeholders to pinpoint unmet needs, prioritize high-value indications, and align R&D investments with patient-centric outcomes.

Key Regional Insights Shaping Autologous Therapies

Regional dynamics are reshaping the delivery and adoption of autologous cell therapies across three primary markets. In the Americas, strong venture capital investment, established reimbursement pathways, and leading academic medical centers are fueling innovation and early market entry for cutting-edge treatments. The Europe, Middle East & Africa region is characterized by harmonization efforts under EMA guidelines, collaborative multi-country clinical trials and emerging reimbursement models that reward value-based outcomes. Rapid regulatory modernization, increasing local manufacturing capacity, and government-backed innovation initiatives in the Asia-Pacific market are accelerating clinical approvals, particularly in Japan, South Korea and Australia. Cross-regional partnerships are on the rise, with technology transfer agreements and multicenter research programs bridging knowledge gaps and standardizing best practices on a global scale. Understanding these regional insights is instrumental for companies aiming to optimize market entry strategies and tailor stakeholder engagement plans.

Key Company Developments in Autologous Cell Therapies

The competitive landscape spans a diverse array of organizations from early-stage pioneers to established biopharma players. Abata Therapeutics and Achilles Therapeutics plc are exploring next-generation T-cell receptor platforms, while Adaptimmune Therapeutics PLC has advanced MAGE-targeted autologous cell therapies into late-stage studies. Adicet Bio Inc. and AIVITA Biomedical, Inc. are developing novel NK cell and dendritic cell-based approaches, respectively, and Aspen Neuroscienc Inc. is investigating autologous neurotrophic factor delivery for central nervous system repair. Bellicum Pharmaceuticals, Inc. continues to refine its inducible safety switch technology, and BioLineRx Ltd. focuses on proprietary small-molecule enhancers for cell engraftment. BioSpace, Inc. and BrainStorm Cell Limited. are notable for their platforms targeting neurodegenerative and inflammatory conditions. Bristol-Myers Squibb Company and Catalent, Inc. are leveraging scale-up expertise to accelerate commercial readiness. Cell Therapy Catapult Ltd. and Fate Therapeutics Inc. champion modular manufacturing and iPSC-derived NK cell therapies. GentiBio, Inc. and IASO BioTherapeutics are pioneering genome-edited cell lines, while Kyverna Therapeutics, Inc. and NOVADIP Biosciences S.A. explore novel delivery vectors. Orchard Therapeutics Inc. has established leadership in inherited metabolic disorders, and T-knife Therapeutics, Inc. applies T-cell receptor engineering to solid tumors. ThermoGenesis Holdings, Inc. and Triumvira Immunologics Inc. are optimizing automated manufacturing, and Vita Therapeutics, Inc. rounds out the landscape with advanced monocyte-derived initiatives. Collectively, these companies exemplify the breadth and depth of innovation driving the field forward.

Actionable Recommendations for Industry Leaders

To navigate the evolving autologous cell therapy ecosystem, industry leaders should prioritize several actionable strategies. First, invest in distributed manufacturing networks that leverage regional centers of excellence to reduce lead times and tariff exposure. Second, forge cross-sector consortia to negotiate bulk procurement of critical reagents and equipment, thereby insulating programs from supply-chain volatility. Third, integrate advanced analytics and digital biomarkers into clinical protocols to enhance patient stratification, optimize dosing regimens and accelerate go-to-market decision-making. Fourth, pursue iterative dialogue with regulatory authorities to align on adaptive trial designs and real-time data submission, ensuring accelerated reviews for breakthrough designations. Finally, cultivate collaborative research partnerships with academic institutions and contract development organizations to share risk, pool expertise and co-develop next-generation platforms. By executing these recommendations, decision-makers can maintain competitive differentiation while delivering sustainable, patient-centric innovations.

Conclusion: Navigating the Future of Autologous Therapies

Autologous cell therapies stand at the cusp of a new era in personalized medicine, underpinned by technological breakthroughs, strategic collaborations and evolving regulatory paradigms. While challenges related to cost, manufacturing scale-up and tariff impacts persist, the field’s rapid pace of innovation and expanding clinical evidence base offer compelling opportunities for transformative patient outcomes. By aligning segmentation insights, regional strategies and collaborative frameworks, stakeholders can chart a path forward that balances agility with rigor. Continued investment in platforms that enhance precision, safety and accessibility will be essential to translating autologous approaches from pioneering treatments into standard-of-care offerings across a spectrum of diseases.

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cell Therapy Platforms
    • Hematopoietic Stem Cells
    • Mesenchymal Stem Cells
  • Gene Modification Techniques
    • CRISPR/Cas9
    • Zinc Finger Nucleases
  • Cardiovascular Diseases
    • Chronic Heart Failure
    • Myocardial Infarction
  • Oncology
    • Hematologic Cancers
      • Leukemias
      • Lymphomas
    • Solid Tumors
      • Breast Cancer
      • Lung Cancer
  • Academic And Research Institutes
    • Clinical Research Organizations
    • University Laboratories
  • Commercial Support
    • Biotechnology Companies
    • Pharmaceutical Companies
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Allogeneic Cell Therapies
  • Autologous Cell Therapies
    • Combination Therapy
    • Monotherapy
  • Autoimmune Diseases
    • Multiple Sclerosis
      • Primary Progressive MS
      • Relapsing-Remitting MS
    • Rheumatoid Arthritis
  • Regenerative Medicine
    • Tissue Engineering
    • Wound Healing
  • Ex Vivo Expansion
  • In Vivo Stimulation
  • Adipose Tissue-Derived Cells
  • Bone Marrow-Derived Cells

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Autologous Cell Therapies Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abata Therapeutics
  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics PLC
  • Adicet Bio Inc.
  • AIVITA Biomedical, Inc.
  • Aspen Neuroscienc Inc.
  • Bellicum Phamaceuticals, Inc.
  • BioLineRx Ltd.
  • BioSpace, Inc.
  • BrainStorm Cell Limited.
  • Bristol-Myers Squibb Company
  • Carisma Therapeutics Inc.
  • Catalent, Inc.
  • Cell Therapy Catapult Ltd.
  • Fate Therapeutics Inc.
  • GentiBio, Inc.
  • IASO BioTherapeutics
  • Kyverna Therapeutics, Inc.
  • NOVADIP Biosciences S.A.
  • Orchard Therapeutics Inc.
  • T-knife Therapeutics, Inc.
  • ThermoGenesis Holdings, Inc.
  • Triumvira Immunologics Inc.
  • Vita Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autologous Cell Therapies Market, by Technology Type
8.1. Introduction
8.2. Cell Therapy Platforms
8.2.1. Hematopoietic Stem Cells
8.2.2. Mesenchymal Stem Cells
8.3. Gene Modification Techniques
8.3.1. CRISPR/Cas9
8.3.2. Zinc Finger Nucleases
9. Autologous Cell Therapies Market, by Application
9.1. Introduction
9.2. Cardiovascular Diseases
9.2.1. Chronic Heart Failure
9.2.2. Myocardial Infarction
9.3. Oncology
9.3.1. Hematologic Cancers
9.3.1.1. Leukemias
9.3.1.2. Lymphomas
9.3.2. Solid Tumors
9.3.2.1. Breast Cancer
9.3.2.2. Lung Cancer
10. Autologous Cell Therapies Market, by End-User
10.1. Introduction
10.2. Academic And Research Institutes
10.2.1. Clinical Research Organizations
10.2.2. University Laboratories
10.3. Commercial Support
10.3.1. Biotechnology Companies
10.3.2. Pharmaceutical Companies
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Autologous Cell Therapies Market, by Treatment Type
11.1. Introduction
11.2. Allogeneic Cell Therapies
11.3. Autologous Cell Therapies
11.3.1. Combination Therapy
11.3.2. Monotherapy
12. Autologous Cell Therapies Market, by Therapeutic Area
12.1. Introduction
12.2. Autoimmune Diseases
12.2.1. Multiple Sclerosis
12.2.1.1. Primary Progressive MS
12.2.1.2. Relapsing-Remitting MS
12.2.2. Rheumatoid Arthritis
12.3. Regenerative Medicine
12.3.1. Tissue Engineering
12.3.2. Wound Healing
13. Autologous Cell Therapies Market, by Manufacturing Process
13.1. Introduction
13.2. Ex Vivo Expansion
13.3. In Vivo Stimulation
14. Autologous Cell Therapies Market, by Source Of Cells
14.1. Introduction
14.2. Adipose Tissue-Derived Cells
14.3. Bone Marrow-Derived Cells
15. Americas Autologous Cell Therapies Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Autologous Cell Therapies Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Autologous Cell Therapies Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abata Therapeutics
18.3.2. Achilles Therapeutics plc
18.3.3. Adaptimmune Therapeutics PLC
18.3.4. Adicet Bio Inc.
18.3.5. AIVITA Biomedical, Inc.
18.3.6. Aspen Neuroscienc Inc.
18.3.7. Bellicum Phamaceuticals, Inc.
18.3.8. BioLineRx Ltd.
18.3.9. BioSpace, Inc.
18.3.10. BrainStorm Cell Limited.
18.3.11. Bristol-Myers Squibb Company
18.3.12. Carisma Therapeutics Inc.
18.3.13. Catalent, Inc.
18.3.14. Cell Therapy Catapult Ltd.
18.3.15. Fate Therapeutics Inc.
18.3.16. GentiBio, Inc.
18.3.17. IASO BioTherapeutics
18.3.18. Kyverna Therapeutics, Inc.
18.3.19. NOVADIP Biosciences S.A.
18.3.20. Orchard Therapeutics Inc.
18.3.21. T-knife Therapeutics, Inc.
18.3.22. ThermoGenesis Holdings, Inc.
18.3.23. Triumvira Immunologics Inc.
18.3.24. Vita Therapeutics, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET MULTI-CURRENCY
FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET MULTI-LANGUAGE
FIGURE 3. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PRIMARY PROGRESSIVE MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY RELAPSING-REMITTING MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IN VIVO STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ADIPOSE TISSUE-DERIVED CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW-DERIVED CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 128. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 129. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 130. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 131. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 133. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 134. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 135. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 136. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 138. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 139. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 143. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 144. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 145. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 146. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 147. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 149. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 153. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 154. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 159. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 162. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 163. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 164. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 166. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 230. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 231. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 232. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 233. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 235. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 237. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 238. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 240. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 241. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 245. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 246. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 247. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 248. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 249. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 250. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 251. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 252. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 253. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 255. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 256. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 257. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 258. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 260. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 261. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 264. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 265. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 266. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 267. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 268. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 269. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL THERAPY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 293. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 295. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 296. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGIC CANCERS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 299. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 300. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMERCIAL SUPPORT, 2018-2030 (USD MILLION)
TABLE 301. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 304. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 305. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 306. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 307. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2030 (USD MILLION)
TABLE 308. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 309. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE OF CELLS, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA AUTOLOGOUS CELL THERAP

Companies Mentioned

  • Abata Therapeutics
  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics PLC
  • Adicet Bio Inc.
  • AIVITA Biomedical, Inc.
  • Aspen Neuroscienc Inc.
  • Bellicum Phamaceuticals, Inc.
  • BioLineRx Ltd.
  • BioSpace, Inc.
  • BrainStorm Cell Limited.
  • Bristol-Myers Squibb Company
  • Carisma Therapeutics Inc.
  • Catalent, Inc.
  • Cell Therapy Catapult Ltd.
  • Fate Therapeutics Inc.
  • GentiBio, Inc.
  • IASO BioTherapeutics
  • Kyverna Therapeutics, Inc.
  • NOVADIP Biosciences S.A.
  • Orchard Therapeutics Inc.
  • T-knife Therapeutics, Inc.
  • ThermoGenesis Holdings, Inc.
  • Triumvira Immunologics Inc.
  • Vita Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Pharmaceutical Industry Outlook, 2024 - Product Image

Pharmaceutical Industry Outlook, 2024

  • Report
  • 86 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
Pharmaceutical Validation Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Pharmaceutical Validation Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.